Capital Product Partners L.P. Announces Change to the Board

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capital Product Partners L.P. Announces Change to the Board of Directors

ATHENS, GREECE--(Marketwired - Sep 12, 2014) - Capital Product Partners L.P. (NASDAQ: CPLP) (the "Partnership") announced today that Mr. Nikolaos Syntychakis has resigned as a director of the board of directors of the Partnership (the "Board"), effective September 9, 2014. Mr. Syntychakis was a director appointed by Capital GP L.L.C., the Partnership's general partner. The Partnership's general partner appointed Mr. Petros Christodoulou as a director to replace Mr. Syntychakis. As the Partnership announced on September 8, 2014, Mr. Christodoulou succeeded Mr. Ioannis E. Lazaridis as Chief Executive Officer and Chief Financial Officer of the Partnership's general partner. The initial term of Mr. Christodoulou's appointment to the Board will expire at the Partnership's 2016 annual general meeting.

Brief Biography of Mr. Christodoulou

Mr. Christodoulou was most recently Deputy Chief Executive Officer and Member of the Board of the National Bank of Greece S.A. He served in such capacity and as a member of the Executive Committees of each of the National Bank of Greece and of the Hellenic Banking Association from June 2012 to July 2014. Mr. Christodoulou joined the National Bank of Greece in September 1998 and previously held the positions of Treasurer and General Manager of the bank. In February 2010, Mr. Christodoulou joined the Public Debt Management Agency (PDMA) of the Hellenic Republic as its General Manager at the time that the Sovereign had lost access to the markets. In that capacity, Mr. Christodoulou led the negotiations with the private creditors that led to the largest sovereign debt restructuring in history. Upon its completion in May 2012, Mr. Christodoulou rejoined NBG as Deputy CEO and Member of the Board. Mr. Christodoulou will maintain his position as a Member of the Board of NBG.

Mr. Christodoulou started his career in banking in 1985 with Credit Suisse First Boston in London. In 1987 he moved to Goldman Sachs in London, as Head of Money Markets Trading, and from 1989 to September 1998 he served in several managerial positions with J.P. Morgan in London, initially as Vice President and later as Managing Director of Emerging Markets. Mr. Christodoulou serves as a Chairman on the Board of Directors of Astir Palace S.A. and as a member on the Board of Directors of NBG. He holds a Master in Business Administration (MBA) from Columbia University in New York with a specialization in Finance and Global Markets and a Bachelor of Commerce from the Athens University of Economics and Business.

About Capital Product Partners L.P.

Capital Product Partners L.P. (NASDAQ: CPLP), a Marshall Islands master limited partnership, is an international owner of modern tanker, container and drybulk vessels. The Partnership currently owns 30 vessels, including four Suezmax crude oil tankers, 18 modern MR (Medium Range) product tankers, seven Post Panamax container vessels and one Capesize bulk carrier. All of its vessels are under period charters to BP Shipping Limited, Overseas Shipholding Group Inc., A.P. Moller-Maersk A.S., Hyundai Merchant Marine Co. Ltd., Engen Petroleum, Subtec S.A. de C.V., Cosco Bulk Carrier Co. Ltd. and Capital Maritime.

Forward-Looking Statements

The statements in this press release that are not historical facts may be forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934, as amended). These forward-looking statements involve risks and uncertainties that could cause the stated or forecasted results to be materially different from those anticipated. Unless required by law, we expressly disclaim any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in our views or expectations, to conform them to actual results or otherwise. We assume no responsibility for the accuracy and completeness of the forward-looking statements. We make no prediction or statement about the performance of our common units.

CPLP-F

Contact Details: Capital GP L.L.C. Petros Christodoulou CEO and CFO +30 (210) 4584 950 E-mail: p.christodoulou@capitalpplp.com Investor Relations / Media Nicolas Bornozis Capital Link, Inc. (New York) Tel. +1-212-661-7566 E-mail: cplp@capitallink.com Capital Maritime & Trading Corp. Jerry Kalogiratos Finance Director +30 (210) 4584 950 E-mail: j.kalogiratos@capitalpplp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 49

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 273

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 79

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 290

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 133

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 189

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 675

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 188

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Impact on CRM Visibility and Brand Trust

Updated Category News Views 217

Understanding the Role of AI in CRM Visibility Brandi AI has recently launched its AI Visibility Index series, which offers insightful measurements of how industries are perceived in AI-generated responses. This new series highlights the ways in which customer relationship management (CRM) brands are represented through the lens of advanced AI answer engines. The AI...

Continue Reading
Celldex Therapeutics Thrives Amid Developments with Briquilimab

Updated Category News Views 148

Overview of Celldex Therapeutics and Briquilimab Celldex Therapeutics (NASDAQ: CLDX) is navigating an exciting phase as it explores treatments for chronic conditions like Chronic Inducible Urticaria (CIndU). Analysts have closely observed the efficacy of briquilimab, highlighting its performance through recent studies. Analyst Insights on Celldex and Briquilimab Goldman...

Continue Reading
XPENG's Financial Success in Q3 2024: Key Insights Revealed

Updated Category News Views 238

XPENG's Journey in the Third Quarter of 2024 XPeng Inc. (“XPENG” or “the Company,” NYSE: XPEV and HKEX: 9868) recently disclosed its financial results for the third quarter ended September 30, 2024. This marks a significant period showcasing growth in revenues and vehicle deliveries, reflecting the company's robust strategy in the smart electric vehicle market....

Continue Reading
Apple Inc. Beats Earnings Expectations: Analysts React

Updated Category News Views 144

Apple Inc. Overcomes Challenges with Strong Quarterly Results Apple Inc.‘s latest quarterly performance has generated significant buzz in the tech world. Analysts reveal that the results showcase a resilient company navigating through various market challenges. This performance not only reflects strong sales of products like the iPhone but also highlights impressive...

Continue Reading
Class Action Alert: Investors Have Rights with AMMO, Inc.

Updated Category News Views 237

Class Action Lawsuit Against AMMO, Inc. In a proactive move for investors, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against AMMO, Inc. (NASDAQ: POWW). This suit comes in light of significant losses experienced by investors in the company due to alleged misstatements and omissions regarding its business practices. Understanding the Class...

Continue Reading